European Project Focused on the Development of Nanomedicines against Pancreatic Cancer
The Kick-off meeting of the European Project NoCanTher was held at IMDEA Nanociencia (Madrid) on 10-11th May. During this meeting 35 researchers from the different organizations involved discussed the key issues to be addressed during the first year and the administrative procedures to ensure the success of this innovative project.
The project, financed with more than € 7 million, aims to scale-up a nanoformulation previously developed at IMDEA Nanociencia, for its use in clinical study for treatment of pancreatic cancer.
NoCanTher will be financed 100% by the EU (H2020 Grant No. 685795) and continues the efforts of a previous project (MULTIFUN FP7 Grant No. 262943) also scientifically coordinated at IMDEA Nanociencia. This time, it integrates a consortium of research centres, hospitals and enterprises from Spain, France, Germany, UK and Ireland. The consortium is made up of five Spanish partners: Spanish National Cancer Research Centre – CNIO, Vall d’Hebron Research Institute, Vall d’Hebron Institute of Oncology, Biopraxis, and IMDEA Nanociencia. The other European partners are Trinity College Dublin (Ireland), Jena University Hospital (Germany), Paris Diderot University (France) and the enterprises Resonant Circuits Limited (UK), Immupharma (UK) and Chemicell (Germany).